Covid Vaccine Breakthrough: the Morningstar View

Morningstar analyst Damien Conover looks in detail at the latest vaccine developments from AstraZeneca and Pfizer/BioNTech

Damien Conover 24 November, 2020 | 9:11AM
Facebook Twitter LinkedIn

Pfizer covid vaccine


Following excellent data from Pfizer/BioNTech and Moderna, AstraZeneca (AZN) and partner Oxford University reported favourable phase 3 data on Covid-19 vaccine AZD1222 with an efficacy rate of 90% (low dose) and 62% (full dose) with no major safety issues observed with the initial data cohort. At the low dose, the efficacy looks fairly similar to competitor data, albeit slightly lower than the 94%-95% efficacy reported by others. We are increasing the vaccine’s probability of approval to 90% but given the firm’s commitment to pricing the vaccine at a non-profit level, we don’t expect any impact to Astra’s fair value estimate. However, the quick development of the vaccine reinforces the firm's innovative power and wide moat. With the likely authorisation of a third vaccine, we expect global demands will be more easily satisfied over the next few years.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
AstraZeneca PLC8,942.00 GBX-0.60Rating
GlaxoSmithKline PLC1,424.60 GBX0.27Rating
Johnson & Johnson163.83 USD0.07Rating
Pfizer Inc42.92 USD-0.56Rating
Sanofi SA85.53 EUR0.49Rating

About Author

Damien Conover  is a guest author